Pacira BioSciences, Inc. (PCRX) Social Stream
PACIRA BIOSCIENCES INC (PCRX) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering PACIRA BIOSCIENCES INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 12 | $93 | $54 | $80.916 | $32.65 | 147.83% |
| 2021-12-08 | 12 | $93 | $54 | $81.083 | $32.65 | 148.34% |
| 2021-12-10 | 12 | $97 | $54 | $81.416 | $32.65 | 149.36% |
| 2022-01-07 | 13 | $97 | $54 | $81.538 | $32.65 | 149.73% |
| 2022-01-13 | 13 | $97 | $54 | $81.846 | $32.65 | 150.68% |
| 2022-02-25 | 13 | $97 | $54 | $82.384 | $32.65 | 152.32% |
| 2022-03-01 | 13 | $96 | $54 | $82.615 | $32.65 | 153.03% |
| 2022-04-14 | 11 | $96 | $54 | $81.363 | $32.65 | 149.2% |
| 2022-05-05 | 11 | $96 | $54 | $80.545 | $32.65 | 146.69% |
| 2022-05-13 | 10 | $96 | $54 | $81.6 | $32.65 | 149.92% |
| 2022-06-01 | 9 | $96 | $54 | $83.222 | $32.65 | 154.89% |
| 2022-06-15 | 8 | $96 | $54 | $82.125 | $32.65 | 151.53% |
| 2022-07-21 | 8 | $96 | $54 | $81.625 | $32.65 | 150% |
| 2022-08-01 | 8 | $96 | $54 | $81.125 | $32.65 | 148.47% |
| 2022-08-02 | 8 | $96 | $54 | $80.75 | $32.65 | 147.32% |
| 2022-08-04 | 8 | $96 | $54 | $80.142 | $32.65 | 145.46% |
| 2022-09-21 | 8 | $96 | $54 | $80.125 | $32.65 | 145.41% |
| 2022-10-13 | 7 | $96 | $54 | $80.125 | $32.65 | 145.41% |
| 2022-10-17 | 8 | $96 | $54 | $79.25 | $32.65 | 142.73% |
| 2022-11-02 | 8 | $96 | $54 | $77.777 | $32.65 | 138.21% |
| 2022-11-04 | 9 | $96 | $54 | $75.333 | $32.65 | 130.73% |
| 2022-11-15 | 9 | $96 | $54 | $73.5 | $32.65 | 125.11% |
| 2022-12-21 | 9 | $96 | $50 | $73.1 | $32.65 | 123.89% |
| 2023-01-05 | 9 | $96 | $50 | $70.555 | $32.65 | 116.09% |
| 2023-01-06 | 9 | $96 | $50 | $68.444 | $32.65 | 109.63% |
| 2023-01-17 | 9 | $96 | $50 | $67.888 | $32.65 | 107.93% |
| 2023-01-31 | 9 | $76 | $50 | $60.875 | $32.65 | 86.45% |
| 2023-02-10 | 9 | $69 | $50 | $60 | $32.65 | 83.77% |
| 2023-02-14 | 9 | $69 | $50 | $59.5 | $32.65 | 82.24% |
| 2023-03-01 | 10 | $76 | $50 | $60.777 | $32.65 | 86.15% |
| 2023-04-20 | 10 | $76 | $50 | $60.666 | $32.65 | 85.81% |
| 2023-05-01 | 10 | $76 | $50 | $60.555 | $32.65 | 85.47% |
| 2023-05-05 | 10 | $72 | $50 | $59.888 | $32.65 | 83.42% |
| 2023-07-04 | 10 | $72 | $50 | $59.889 | $32.65 | 83.43% |
| 2023-07-13 | 10 | $72 | $50 | $59.555 | $32.65 | 82.4% |
| 2023-07-21 | 9 | $72 | $50 | $60.5 | $32.65 | 85.3% |
| 2023-07-25 | 9 | $72 | $48 | $59.75 | $32.65 | 83% |
| 2023-08-03 | 9 | $72 | $48 | $57.25 | $32.65 | 75.34% |
| 2023-08-09 | 9 | $68 | $46 | $55.125 | $32.65 | 68.84% |
| 2023-10-13 | 9 | $68 | $46 | $54.5 | $32.65 | 66.92% |
| 2023-10-23 | 10 | $68 | $46 | $54.777 | $32.65 | 67.77% |
| 2023-11-03 | 10 | $68 | $42 | $53.333 | $32.65 | 63.35% |
| 2023-11-06 | 10 | $58 | $42 | $50.777 | $32.65 | 55.52% |
| 2023-11-07 | 10 | $58 | $38 | $49.888 | $32.65 | 52.8% |
| 2023-11-28 | 10 | $58 | $38 | $49.111 | $32.65 | 50.42% |
| 2023-12-20 | 11 | $58 | $38 | $48.4 | $32.65 | 48.24% |
The Trend in the Analyst Price Target
PCRX's average price target has moved down $5.39 over the prior 43 months.
PCRX reports an average of 56.58% for its upside potential over the past 48 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-05-05 | 10 | 72 | 50 | 59.888 | 42.89 | 39.63% |
| 2023-07-13 | 10 | 72 | 50 | 59.555 | 37.26 | 59.84% |
| 2023-07-13 | 9 | 72 | 50 | 59.555 | 37.26 | 59.84% |
| 2023-08-03 | 9 | 72 | 48 | 57.250 | 38.75 | 47.74% |
| 2023-08-09 | 9 | 68 | 46 | 55.125 | 38.06 | 44.84% |
PCRX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.27 | 8 | 3 | 0 | 0 | 0 | 11 |
The Trend in the Broker Recommendations
Over the past 20 months, PCRX's average broker recommendation rating improved by 0.37.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for PCRX as an investment opportunity.
- PCRX has a higher upside potential (average analyst target price relative to current price) than 4626.08% of all US stocks.
- In terms of how PACIRA BIOSCIENCES INC fares relative to Pharmaceutical Products stocks, note that its average analyst price target is greater than 4519.39% of that group.
- PACIRA BIOSCIENCES INC's number of analysts covering the stock is greater than 3983.23% of stocks in the mid market cap category.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, PACIRA BIOSCIENCES INC's variance in analysts' estimates is lower than -1734.98% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to PACIRA BIOSCIENCES INC are EBS, SUPN, and PBH.
View All Top Stocks by Price Target
Is PCRX a Buy, Hold or Sell? See the POWR Ratings now!